$51.42
4.07% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US46266A1097
Symbol
IRMD

iRadimed Corp Stock price

$53.60
+0.31 0.58% 1M
+4.03 8.13% 6M
-1.40 2.55% YTD
+10.89 25.50% 1Y
+10.58 24.60% 3Y
+35.18 190.97% 5Y
+39.12 270.19% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.15 0.28%
ISIN
US46266A1097
Symbol
IRMD
Sector

Key metrics

Market capitalization $681.53m
Enterprise Value $629.45m
P/E (TTM) P/E ratio 35.60
EV/FCF (TTM) EV/FCF 35.72
EV/Sales (TTM) EV/Sales 8.59
P/S ratio (TTM) P/S ratio 9.31
P/B ratio (TTM) P/B ratio 7.85
Dividend yield 0.28%
Last dividend (FY23) $1.67
Revenue growth (TTM) Revenue growth 11.71%
Revenue (TTM) Revenue $73.24m
EBIT (operating result TTM) EBIT $21.96m
Free Cash Flow (TTM) Free Cash Flow $17.62m
Cash position $52.23m
EPS (TTM) EPS $1.51
P/E forward 33.40
P/S forward 8.58
EV/Sales forward 7.93
Short interest 2.95%
Show more

Is iRadimed Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

iRadimed Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a iRadimed Corp forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a iRadimed Corp forecast:

Buy
100%

Financial data from iRadimed Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
73 73
12% 12%
100%
- Direct Costs 17 17
10% 10%
23%
56 56
12% 12%
77%
- Selling and Administrative Expenses 28 28
5% 5%
38%
- Research and Development Expense 5.84 5.84
104% 104%
8%
23 23
10% 10%
31%
- Depreciation and Amortization 0.82 0.82
6% 6%
1%
EBIT (Operating Income) EBIT 22 22
10% 10%
30%
Net Profit 19 19
12% 12%
26%

In millions USD.

Don't miss a Thing! We will send you all news about iRadimed Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

iRadimed Corp Stock News

Neutral
GlobeNewsWire
24 days ago
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference.
Neutral
Seeking Alpha
about 2 months ago
IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Confere...
Neutral
GlobeNewsWire
2 months ago
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
More iRadimed Corp News

Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices and accessories and services. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Head office United States
CEO Roger Susi
Employees 160
Founded 1992
Website www.iradimed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today